ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Arizona's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1991
Meetings & Education
Financial Advocacy & Patient Assistance
TACOS Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Find a Clinical Trial
TACOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Atezolizumab Plus Nab-paclitaxel for TNBC
On March 8, the FDA approved atezolizumab (Tecentriq, Genentech Inc.) plus nab-paclitaxel (Abraxane, Celgene) for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).
Read OncLive news coverage here
Tweets by OSSatACCC